Prostate Cancer
Conditions
Keywords
Inoperable Prostate Cancer, Erectile Dysfunction
Brief summary
Cyproterone acetate (CPA) is a steroidal antiandrogen which has affinity with progesterone and with glucocorticoid receptors. Cyproterone acetate is long-term proven effective treatment of inoperable carcinoma of the prostate. Sexual functions remain very important in men with prostate cancer. However sexual functions are deteriorating fast with course of the disease. The influence of CPA on sexual functions remains controversial. IIEF-5 erectile dysfunction questionnaire is currently widely used validated simple scoring system for diagnosing of erectile dysfunction and belongs to most used systems in Czech Republic. At present there are no data on CPA influence on IIEF-5 scored erectile dysfunction within the use of its indication in prostate cancer.
Interventions
Patients in regular clinical practice receiving Androcur according to local drug information
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males \> 18 years previously untreated with Androcur. * No contraindication to Androcur.
Exclusion criteria
* Liver diseases, malignant liver tumours and wasting diseases (except for carcinoma of the prostate). A history of or existing thrombosis or embolism. Severe chronic depression. Hypersensitivity to cyproterone. Cyproterone acetate in previous therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of treatment with Androcur (concomitant treatment), disease stage, testosterone level, age with erectile dysfunction (measured by IIEF-5 validated questionnaire) | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of PSA level and erectile dysfunction | 6 months |
| Sexual activity of Czech patients with inoperable prostate cancer | 6 months |
Countries
Czechia
Outcome results
None listed